Chief Marketing Officer, Now Investor And Advisor
CurrentFounding member of a veterinary oncology company, moved into an advisory role in 2020 after disrupting the marketplace. Introduced new modalities into the oncology treatment lifecycle and gave families hope (and pets a new lease on life). Took the company from $0 to $17M in annual revenue and positioned Petcure for acquisition in 2021 at a 12X multiple. Orchestrated growth with the strategic placement of clinics, blanketing the US, and introducing new access to care. Differentiated Petcure’s level of care as the 1st company to transition stereotactic radiosurgery (SRS) from humans to veterinary medicine. Clearly articulated this core distinction and wove this new approach into the branding, beginning with the name Petcure. Set a new standard in patient satisfaction, crushing industry standards and delivering an NPS averaging 25 points higher (low 90s) than competitors. With no margin for error, baked empathy, responsiveness, and capability into the Petcure’s DNA.